Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Diabetic nephropathy (DN) often leads to end-stage renal disease. Oxidative stress
demonstrates a crucial act in the onset and progression of DN, which triggers various …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

Abstract Background This Obesity Medicine Association (OMA) Clinical Practice Statement
(CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), an …

Diabetic kidney disease (DKD) has become the leading cause of end-stage renal disease
(ESRD), and the prevalence of DKD has increased worldwide during recent years. DKD is …

Diabetic kidney disease (DKD) is a severe and common complication and affects a quarter
of patients with type 2 diabetes mellitus (T2DM). Oxidative stress and inflammation related to …

Aims: Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease.
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) showed excellent renoprotective …

Current management of chronic kidney disease (CKD) in type 1 diabetes centres on
glycaemic control, renin–angiotensin system inhibition and optimisation of risk factors …

The lipid kinase VPS34 orchestrates autophagy, endocytosis, and metabolism and is
implicated in cancer and metabolic disease. The proximal tubule in the kidney is a key …

Diabetes mellitus (DM) is a metabolic disorder majorly arising from the pathophysiology of
the pancreas manifested as a decline in the insulin production or the tissue's resistance to …